Lack of the type III epidermal growth factor receptor mutation in colorectal cancer

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4889-4893

  Spindler, Karen Lise Garm ^a,c   Olsen, Dorte Aalund ^a   Nielsen, Jens Nederby ^a   Brandslund, Ivan ^a   Poulsen, Hans Skovgaard ^b   Villingshøj, Mette ^b   Jakobsen, Anders ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

Author keywords

Colorectal cancer; EGFRvIII; Mutation; PCR; Western blot

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33845941005     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94(2): 153-156, 2001.
2. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23(9): 1803-1810, 2005.
3. Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2(4): 246-251, 2003.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345, 2004.
5. Spaulding DC and Spaulding BO: Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol 29(5 Suppl 14): 45-54, 2002.
6. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2): 127-137, 2001.
7. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20(18 Suppl): 1S-13S, 2002.
8. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14): 2787-2799, 2003.
9. Tang P, Steck PA and Yung WK: The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol 35(3): 303-314, 1997.
10. Chaffanet M, Chauvin C, Laine M, Berger F, Chedin M, Rost N et al: EGF receptor amplification and expression in human brain tumours. Eur J Cancer 28(1): 11-17, 1992.
11. Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard GF et al: Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 11(4): 1368-1371, 2005.
12. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C et al: Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 11(18): 6650-6656, 2005.
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139, 2004.
14. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW et al: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55(23): 5536-5539, 1995.
15. Pedersen MW, Meltorn M, Damstrup L and Poulsen HS: The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12(6): 745-760, 2001.
16. Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike HM et al: Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83(11): 917-926, 2005.
17. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB and Wong AJ: Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273(1): 200-206,1998.
18. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS et al: Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6(10): 1251-1259, 1995.
19. Tang CK, Gong XQ, Moscatello DK, Wong AJ and Lippman ME: Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 60(11): 3081-3087, 2000.
20. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR et al: Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82(1): 186-194, 2000.
21. Feldkamp MM, Lala P, Lau N, Roncari L and Guha A: Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45(6): 1442-1453, 1999.
22. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C et al: Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 27(2): 317-325, 2005.
23. Lindebjerg J, Nielsen JN, Hoeffding LD, Bisgaard C, Brandslund I and Jakobsen A: Expression of thymidylate synthase in primary colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol 14(1): 37-41, 2006.
24. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H et al: Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 17(8): 895-904.
25. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F et al: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6(5): 279-286, 2005.
26. Sauer T, Guren MG, Noren T and Dueland S: Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy? Histopathology 47(6): 560-564, 2005.